Appendix 3B — Renounceable Rights Issue

Mar 25, 2020
Posted in: Investor updates

Home » Appendix 3B — Renounceable Rights Issue

Appendix 3B — Renounceable Rights Issue

Mar 25, 2020
Posted in: Investor updates

Imagion Biosystems Limited has released Appendix 3B — Renounceable Rights Issue. Read Appendix 3B.

Imagion Initiates Collaboration with Wayne State University to Develop Advanced Molecular Imaging Capabilities to Enable AI Cancer Diagnostics

August 13, 2025

Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilizing its proprietary MagSense® imaging

IBX Secures Firm Commitments for A$3.5M Capital Raising

August 4, 2025

Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer cells utilising its proprietary MagSense®

Imagion MagSense Breast Cancer Program Phase 2 Clinical Trial Update

July 15, 2025

Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.

Appendix 3B — Renounceable Rights Issue

Appendix 3B — Renounceable Rights Issue

Related Articles

Imagion Initiates Collaboration with Wayne State University to Develop Advanced Molecular Imaging Capabilities to Enable AI Cancer Diagnostics

IBX Secures Firm Commitments for A$3.5M Capital Raising

Imagion MagSense Breast Cancer Program Phase 2 Clinical Trial Update

Transforming medical imaging for early disease detection

About Imagion Biosystems

Contact us

Join our email list